

HER2-Positive Early Breast Cancer

A Personalized Approach to Treatment **IME**

Saturday, 28 September 2019 | 18:30 – 20:00

Cartagena Auditorium, Hall 3
Fira Gran Via, Barcelona, Spain

Chair

Martine Piccart, MD, PhD
Institut Jules Bordet
Brussels, Belgium

Faculty

Javier Cortés, MD, PhD
IOB Institute of Oncology, Madrid
and Barcelona
Vall d'Hebron Institute of
Oncology (VHIO)
Medica Scientia Innovation
Research (MedSIR)
Barcelona, Spain

Sara Hurvitz, MD, FACP
University of California, Los Angeles
UCLA Jonsson Comprehensive
Cancer Center
Los Angeles, California, United States

Sibylle Loibl, MD, PhD
German Breast Group, Neu-Isenburg
Centre for Haematology and
Oncology Bethanien
Frankfurt, Germany

Agenda

18:30	Welcome and introduction Martine Piccart, MD, PhD
18:32	“Test your knowledge” interactive quiz Martine Piccart, MD, PhD
18:35	Getting to grips with the biology of HER2-positive breast cancer Sara Hurvitz, MD, FACP
18:50	Q&A
18:55	Neoadjuvant treatment strategies for HER2-positive early breast cancer: Should treatment recommendations be response-based? Sibylle Loibl, MD, PhD
19:15	Q&A
19:20	Risk-adapted treatments for HER2- positive early breast cancer Javier Cortés, MD, PhD
19:40	Q&A
19:45	Developing a roadmap for the treatment of HER2-positive early breast cancer: One size no longer fits all Martine Piccart, MD, PhD
19:55	Conclusions and prIME Points™ Martine Piccart, MD, PhD
20:00	Adjourn

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Sunshine Act/EFPIA Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.